BIONET Therapeutics Corp. (TPEX:7808)

Market Cap	4.04B
Revenue (ttm)	105.67M
Net Income (ttm)	-100.46M
Shares Out	70.00M
EPS (ttm)	-1.49
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	213,405
Average Volume	230,276
Open	60.90
Previous Close	60.70
Day's Range	56.50 - 60.90
52-Week Range	37.70 - 72.60
Beta	n/a
RSI	55.69
Earnings Date	Sep 17, 2025

About BIONET Therapeutics

BIONET Therapeutics Corp., a biopharmaceutical company, develops cell therapy products and drug development for acute and severe diseases. The company develops treatment for adult respiratory distress syndrome, pulmonary fibrosis, chronic kidney failure, acute wound healing, chronic wound healing of diabetic ulcers, osteoarthritis, and dry eye syndrome. It also provides CRDMO services. The company was founded in 2022 and is based in Taipei, Taiwan.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2022
• Employees: 73
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 7808

Financial Performance

In 2024, BIONET Therapeutics's revenue was 81.32 million, an increase of 1414.60% compared to the previous year's 5.37 million. Losses were -86.26 million, 131.0% more than in 2023.